World Health Organization. Global tuberculosis report 2020. In: Global tuberculosis report 2020. 2020.
Musa BM, Adamu AL, Galadanci NA, Zubayr B, Odoh CN, Aliyu MH. Trends in prevalence of multi drug resistant tuberculosis in sub-Saharan Africa: A systematic review and meta-analysis. PLoS ONE [Internet]. 2017 Sep 25 [cited 2019 Apr 21];12(9). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612652/
Otu J, Gehre F, Zingue D, Kudzawu S, Forson A, Mane M, et al. Multidrug-resistant tuberculosis (mdr-Tb): an emerging problem in West Africa. BMJ Glob Health. 2017;2(Suppl 2):A32–3.
Article
Google Scholar
Kibret KT, Moges Y, Memiah P, Biadgilign S. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies. Infect Dis Poverty. 2017;6(1):7.
Article
Google Scholar
Meressa D, Hurtado RM, Andrews JR, Diro E, Abato K, Daniel T, et al. Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia–an observational cohort study. Thorax. 2015;70(12):1181–8.
Article
Google Scholar
Kliiman K, Altraja A. Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J. 2009;33(5):1085–94.
Article
CAS
Google Scholar
Leveri TH, Lekule I, Mollel E, Lyamuya F, Kilonzo K. Predictors of treatment outcomes among multidrug resistant tuberculosis patients in Tanzania [Internet]. Tuberculosis Research and Treatment. 2019 [cited 2019 Apr 21]. https://www.hindawi.com/journals/trt/2019/3569018/ref/
Samuels JP, Sood A, Campbell JR, Ahmad Khan F, Johnston JC. Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis. Sci Rep [Internet]. 2018 Mar 21 [cited 2019 Apr 21];8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862834/
Tang S, Tan S, Yao L, Li F, Li L, Guo X, et al. Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigation. PLoS ONE [Internet]. 2013 Dec 5 [cited 2019 Apr 21];8(12). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857781/
Zhang Y, Wu S, Xia Y, Wang N, Zhou L, Wang J, et al. Adverse events associated with treatment of multidrug-resistant tuberculosis in china: an ambispective cohort study. Med Sci Monit Int Med J Exp Clin Res. 2017;18(23):2348–56.
Google Scholar
Chang K-C, Yew W-W, Tam C-M, Leung C-C. WHO Group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis. Antimicrob Agents Chemother. 2013;57(9):4097–104.
Article
CAS
Google Scholar
Winters N, Butler-Laporte G, Menzies D. Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. Eur Respir J. 2015;46(5):1461–70.
Article
CAS
Google Scholar
Migliori GB, Sotgiu G, D’Ambrosio L, Centis R, Lange C, Bothamley G, et al. TB and MDR/XDR-TB in European union and European economic area countries: managed or mismanaged? Eur Respir J. 2012;39(3):619–25.
Article
CAS
Google Scholar
Water BJ van de, Silva SG, Bettger JP, Humphreys J, Cunningham CK, Farley JE. Provision of guideline-based care for drug-resistant tuberculosis in South Africa: level of concordance between prescribing practices and guidelines. PLOS ONE. 2018 Nov 5;13(11):e0203749.
WHO | Policy Implementation Package for new TB drug introduction [Internet]. WHO. [cited 2019 Apr 17]. https://www.who.int/tb/publications/implementation-new-tb-drugs/en/
D’Ambrosio L, Bothamley G, Caminero Luna JA, Duarte R, Guglielmetti L, Muñoz Torrico M, et al. Team approach to manage difficult-to-treat TB cases: experiences in Europe and beyond. Pulmonology. 2018;24(2):132–41.
Article
Google Scholar
Tiberi S, Pontali E, Tadolini M, D’Ambrosio L, Migliori GB. Challenging MDR-TB clinical problems–the case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2019;80S:S68-72.
Google Scholar
National Tuberculosis and Leprosy Control Program. Uganda National Guidelines for the Programmatic Management of Drug Resistant Tuberculosis [Internet]. Kampala: Ministry of Health; 2011 p. 47. Available from: https://elearning.idi.co.ug/pluginfile.php/5676/mod_page/content/5/National%20Drug%20Resistant%20-TB%20Guidelines.pdf
Esposito S, D’Ambrosio L, Tadolini M, Schaaf HS, Luna JC, Marais B, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J. 2014;44(3):811–5.
Article
Google Scholar
Baluku JB, Nakazibwe B, Naloka J, Nabwana M, Mwanja S, Mulwana R, et al. Treatment outcomes of drug resistant tuberculosis patients with multiple poor prognostic indicators in Uganda: A countrywide 5-year retrospective study. J Clin Tuberc Mycobact Dis. 2021;23:100221.
Google Scholar
Kasozi S, Kirirabwa NS, Kimuli D, Luwaga H, Kizito E, Turyahabwe S, et al. Addressing the drug-resistant tuberculosis challenge through implementing a mixed model of care in Uganda. PLOS ONE. 2020;15(12):e0244451.
Article
CAS
Google Scholar
World Health Organization. Definitions and reporting framework for tuberculosis–2013 revision. World Health Organization; 2013. Report No.: 9241505346.
Eller LA, Eller MA, Ouma B, Kataaha P, Kyabaggu D, Tumusiime R, et al. Reference Intervals in Healthy Adult Ugandan Blood Donors and Their Impact on Conducting International Vaccine Trials. PLOS ONE. 2008;3(12):e3919.
Article
Google Scholar
Malangu N, Adebanjo OD. Knowledge and practices about multidrug-resistant tuberculosis amongst healthcare workers in Maseru. Afr J Prim Health Care Fam Med [Internet]. 2015 Mar 27 [cited 2021 Mar 18];7(1). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4564896/
Alene KA, Adane AA, Yifiru S, Bitew BD, Adane A, Koye DN. Knowledge and practice of health workers about control and prevention of multidrug-resistant tuberculosis in referral hospitals, Ethiopia: a cross-sectional study. BMJ Open. 2019;9(2):e022948.
Article
Google Scholar
Isara A, Akpodiete A. Concerns about the knowledge and attitude of multidrug-resistant tuberculosis among health care workers and patients in Delta State. Nigeria Niger J Clin Pract. 2015;18(5):664–9.
Article
CAS
Google Scholar
Guglielmetti L, Jaffré J, Bernard C, Brossier F, El Helali N, Chadelat K, et al. Multidisciplinary advisory teams to manage multidrug-resistant tuberculosis: the example of the French Consilium. Int J Tuberc Lung Dis. 2019;23(10):1050–4.
Article
CAS
Google Scholar
Pontali E, Raviglione MC, Migliori GB. Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives. Eur Respir Rev [Internet]. 2019 Jun 30 [cited 2021 Mar 19];28(152). https://err.ersjournals.com/content/28/152/190035
Huang GKL, Pawape G, Taune M, Hiasihri S, Ustero P, O’Brien DP, et al. Telemedicine in Resource-Limited Settings to Optimize Care for Multidrug-Resistant Tuberculosis. Front Public Health [Internet]. 2019 [cited 2021 Mar 19];7. Available from: https://www.frontiersin.org/articles/https://doi.org/10.3389/fpubh.2019.00222/full
Morris L, Hiasihri S, Chan G, Honjepari A, Tugo O, Taune M, et al. The emergency response to multidrug-resistant tuberculosis in Daru, Western Province, Papua New Guinea, 2014–2017. Public Health Action. 2019;9(Suppl 1):S4-11.
Article
CAS
Google Scholar